The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring

AIDS

Volumn 26, Issue 1, 2012, Pages 57-65

  Gsponer, Thomas ^a   Petersen, Maya ^b   Egger, Matthias ^a,c   Phiri, Sam ^d   Maathuis, Marloes H ^e   Boulle, Andrew ^c   Musondad, Patrick ^f,g   Tweya, Hannock ^d   Peter, Karin ^e   Chi, Benjamin H ^g,h   Keiser, Olivia ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d KAMUZU CENTRAL HOSPITAL   (Malawi)

^e ETH ZURICH   (Switzerland)

^f UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^g CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

antiretroviral therapy; immunological failure; loss to follow up; Malawi; marginal structural models; mortality; second line therapy; treatment failure; viral load monitoring; Zambia

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALAWI; MALE; MORTALITY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS LOAD; ZAMBIA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV-1; HUMANS; MALAWI; MALE; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD; ZAMBIA;

EID: 82455212839     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834e1b5f     Document Type: Article

References (30)

1. HIV treatment reaching 6.6 million people, but majority still in need. Geneva: World Health Organization; 2011 Available from http://www.who.int/ mediacentre/news/releases/2011/hivtreatement-20110603/en/index.html. [Accessed 9 November 2011]
2. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5:e148.
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Geneva: World Health Organization; 2010. pp. 1-359 Available from http://whqlibdoc. who.int/publications/2010/9789241599764-eng.pdf. [Accessed 9 November 2011]
4. Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009; 14:1220-1225.
5. Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23:1867-1874.
6. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-termeffectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378-384.
7. Robins J, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
8. Hernan MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008; 19:766-779.
9. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656-664.
10. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2011. [Epub ahead of print] 11.
11. Goldman JD, Cantrell RA, Mulenga LB, Tambatamba BC, Reid SE, Levy JW, et al. Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1031-1035.
12. Hernan MA, Wolfe F, Tilling K, Choi H, Sterne JA. Controlling for time-dependent confounding using marginal structural modelsA1: Fewell. Z Stata Journal 2004; 4:402-420.
13. Gelman A, Jakulin A, Pittau MG, Su YS. A weakly informative default prior distribution for logistic and other regression models. Ann Appl Stat 2008; 2:1360-1383.
14. Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, Boulle A, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010; 15:251-258.
15. Pujades-Rodriguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. J Am Med Assoc 2010; 304:303-312.
16. Hernan MA, Brumback B, Robins J. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-569.
17. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
18. Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11:510-518.
19. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009; 50:529-536.
20. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS 2011; 25:1761-1769.
21. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al. Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS 2011; 25:1189-1197.
22. Bastard M, Koita Fall MB, Laniece I, Taverne B, Desclaux A, Ecochard R, et al. Revisiting long-term adherence to HAART in Senegal using latent class analysis. J Acquir Immune Defic Syndr 2011. [Epub ahead of print].
23. Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviraltreated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48: 115-122.
24. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559-567.
25. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009; 4:e5790.
26. Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, Christopoulos KA, et al. Retention in care among HIVinfected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep 2010; 7: 234-244.
27. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
28. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
29. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Internal Med 2011; 154:509-515.
30. VanderWeele TJ, Hernan MA, Robins JM. Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology 2008; 19:720-728.